The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
 
Magali lacroix-Triki
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; MSD Oncology; Myriad Genetics; Roche Diagnostics Solutions
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Exact Sciences
 
Robert Gray
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); Janssen-Ortho (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Sequenta (Inst); Syndax (Inst); Takeda (Inst)
 
Valentin Gaury
Employment - Owkin
 
Victor Aubert
No Relationships to Disclose
 
Estelle Hocquet
Employment - Owkin
 
Damien Jacobs
Employment - Owkin
 
Ingrid Garberis
No Relationships to Disclose
 
Glenn Broeckx
Honoraria - AstraZeneca
Consulting or Advisory Role - Imagene AI; Johnson & Johnson/Janssen; Roche
Speakers' Bureau - Novartis
Research Funding - Owkin
 
Christine Desmedt
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst)
Research Funding - Menarini Group (Inst)
Expert Testimony - Lilly (Inst)
 
Alexander Lazar
Leadership - Archer; Iterion Therapeutics; Modella; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; BMS; Deciphera; Moderna/Merck Collaboration; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Sunil Badve
Honoraria - Agilent; AstraZeneca; Bristol Myers Squibb Foundation; Ventana Medical Systems
Speakers' Bureau - Agilent; AstraZeneca; Targos
Research Funding - Bristol Myers Squibb Foundation (Inst); Caris Life Sciences (Inst); Dako/Agilent Technologies (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - E-Score for predicting recurrence of DCIS (Inst); EarlyR - signature for ER+ breast cancer (Inst)
 
Fabrice Andre
Consulting or Advisory Role - AstraZeneca (Inst); Boston Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Lilly; Lilly (Inst); N-Power Medicine (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Relay Therapeutics; Relay Therapeutics (Inst); ROCHE (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Guardant Health (Inst); Lilly (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Sherene Loi
Honoraria - Adanate; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Joseph Sparano
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; General Dynamics Information Technology (GDIT); Lyell Immunopharma; Novartis; NPJ Breast Cancer; Pfizer; UpToDate
Research Funding - Olema Pharmaceuticals (Inst)
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; AstraZeneca; BMS; Case45; Daicchii Sankyo; Roche
Speakers' Bureau - AstraZeneca; Daicchii Sankyo; Exact Sciences
Research Funding - Merck; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Case45; Daichii Sankyo; Merck; Roche